Status:
COMPLETED
Meningiomas and Treatment With CYPROTERONE ACETATE or Progestin
Lead Sponsor:
University Hospital, Brest
Conditions:
Meningioma
Eligibility:
All Genders
18+ years
Brief Summary
Investigators observe an increase risk of meningioma in patient treated by CYPROTERONE ACETATE or other form of progestin. Investigatorsdiscribe caractéristics of meningioma and treatement of the pati...
Detailed Description
Retrospective study in CHRU of brest, the investigators selected patient with history of méningioma and treated by CYPROTERONE ACETATE, CHLORMADINONE ACETATE and NOMEGESTROL ACETATE essentially The in...
Eligibility Criteria
Inclusion
- minimum 18 years
- medical follow up in CHRU of Brest
- treated by CYPROTERONE ACETATE and/or CHLORMADINONE ACETATE NOMEGESTROL ACETATE, PROGESTERONE , DYDROGESTERONE PROMEGESTONE , NORETHISTERONE, LEVONORGESTREL , oestroprogestogenic contraception
- meningioma after treatement by progestin or CYPROTERONE ACETATE
Exclusion
- history ofbreast cancer
- history of cerebral radiotherapy
- history of neurofibromatosis
- meningioma before treatement by progestin or CYPROTERONE ACETATE
- minor patient
Key Trial Info
Start Date :
February 25 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2019
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT04109404
Start Date
February 25 2019
End Date
June 1 2019
Last Update
October 11 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Département de Nutrition - CHRU de Brest
Brest, France, 29200